Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.

Détails

Ressource 1Télécharger: Butticaz (CCR5), Antiviral Ther 2003.pdf (217.38 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_488CC1E156F2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.
Périodique
Antiviral therapy
Auteur⸱e⸱s
Butticaz C., Ciuffi A., Muñoz M., Thomas J., Bridge A., Pebernard S., Iggo R., Meylan P., Telenti A.
ISSN
1359-6535
Statut éditorial
Publié
Date de publication
2003
Peer-reviewed
Oui
Volume
8
Numéro
5
Pages
373-7
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
Stable gene silencing by RNA interference (RNAi) can be achieved by expression of small hairpin RNAs (shRNAs) from RNA polymerase III promoters. We have tested lentiviral vectors expressing shRNAs targetting CCR5 in primary CD4 T cells from donors representing various CCR5 and CCR2 genetic backgrounds covering the full spectrum of CCR5 expression levels and permissiveness for HIV-1 infection. A linear decrease in CCR5 expression resulted in a logarithmic decrease in cellular infection, giving up to three logs protection from HIV-1 infection in vitro. Protection was maintained at very high multiplicity of infection. This and other recent reports on RNAi should open a debate about the use of RNAi gene therapy for HIV infection.
Mots-clé
CD4-Positive T-Lymphocytes, Cells, Cultured, Gene Silencing, Gene Therapy, Genetic Vectors, HIV Infections, HIV-1, Humans, Lentivirus, RNA Interference, RNA, Small Interfering, Receptors, CCR5
Pubmed
Web of science
Création de la notice
25/01/2008 15:45
Dernière modification de la notice
18/05/2023 7:10
Données d'usage